Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.

D Russell-Jones; RM Cuddihy; M Hanefeld; A Kumar; JG González; M Chan; AM Wolka; MK Boardman; DURATION-4 Study Group

doi:10.2337/dc11-1107

Back

Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.

Journal article

Peer reviewed

Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.

D Russell-Jones, RM Cuddihy, M Hanefeld, A Kumar, JG González, M Chan, AM Wolka, MK Boardman and DURATION-4 Study Group

Diabetes Care, Vol.35(2), pp.252-258

02/2012

DOI: https://doi.org/10.2337/dc11-1107

Abstract

Diabetes Mellitus

Type 2

Double-Blind Method

Drug Administration Schedule

Female

Humans

Hypoglycemic Agents

Male

Metformin

Middle Aged

Pyrazines

Thiazolidinediones

Treatment Outcome

Triazoles

Venoms

Peptides

To test the safety and efficacy of exenatide once weekly (EQW) compared with metformin (MET), pioglitazone (PIO), and sitagliptin (SITA) over 26 weeks, in suboptimally treated (diet and exercise) drug-naive patients with type 2 diabetes.

Metrics

29 Record Views

283 Times Cited - Web of Science

See more details

Details

Title: Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.
Creators: D Russell-Jones
RM Cuddihy
M Hanefeld
A Kumar
JG González
M Chan
AM Wolka
MK Boardman
DURATION-4 Study Group
Publication Details: Diabetes Care, Vol.35(2), pp.252-258
Date published: 02/2012
Date submitted: 17/05/2017
Identifiers: 99516971902346
Academic Unit: School of Biosciences; University of Surrey
Language: English
Resource Type: Journal article

Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.

Abstract

Metrics

Details

Usage Policy